CHICAGO, Illinois, February 20, 2009 ¬ KMR GROUP, a firm analyzing biopharmaceutical R&D performance, announces the launch of a Biologics R&D Study to assess recent developments in biologics, including monoclonal antibodies and recombinant proteins, with a focus on the successes and challenges across the research & development spectrum. The benchmarking study, beginning this spring, will encompass biologics capability through technology acquisitions, licensing opportunities, and in-house development.
IMPORTANT QUESTIONS ANSWERED IN THIS STUDY
What is the current state of biologics R&D in the Industry in terms of investment, pipeline, and manufacturing capability and how does my company compare? Where is the industry heading? What factors will influence and shape the rate of growth in large molecule development?
What are the baseline key performance measures pertaining to success rates, cycle times, and overall volume of NMEs in the pipeline for large molecules? How do these measures compare to small molecule development?
How are companies balancing the need for large molecule manufacturing capabilities with the huge investment requirements that they entail?
In what areas are companies developing internal capacity and capabilities? What types of services are being outsourced or off-shored? Does the capabilities spectrum depend on a company’s stage of maturity with respect to large molecule development? How important is it to have large molecule manufacturing capabilities internally?
KMR is now recruiting participants for the study.
“We are providing leading biopharmaceutical companies with an in-depth analysis of Biologics R&D so that they can better understand, based on reliable and confidential comparative data, how their organization is faring in the Biologics arena and how they can use this analysis to answer key business questions.” commented Linda Martin, Principal of KMR GROUP.
